Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada

Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada

CAR-T cell therapy has significantly improved outcomes for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but challenges such as limited resources, manufacturing timelines, and notable toxicities persist. Bispecific antibodies (BsAbs), including glofitamab and epco...

Full description

Saved in:
Bibliographic Details
Main Authors: Isabelle Fleury, David MacDonald, Mona Shafey, Anna Christofides, Laurie H. Sehn
Format: Article
Language:English
Published: MDPI AG 2025-02-01
Series:Current Oncology
Subjects:
CAR-T therapy
bispecific antibodies
glofitamab
epcoritamab
diffuse large B-cell lymphoma
relapsed/refractory lymphoma
Online Access:https://www.mdpi.com/1718-7729/32/3/142
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1718-7729/32/3/142

Similar Items